Mark Eisner - 21 Feb 2026 Form 4 Insider Report for Zura Bio Ltd (ZURA)

Reporting relationship: Director
Issuer ticker: ZURA
Reported as of: 21 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2026, 21:14:02 UTC
Prior SEC filing: 17 Jul 2025
Next SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kim Davis, Attorney-in-Fact

Key filing fact

Mark Eisner filed Form 4 for Zura Bio Ltd (ZURA) on 24 Feb 2026.

Key facts

This page summarizes Mark Eisner's Form 4 filing for Zura Bio Ltd (ZURA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2026, 21:14.

Change

Previous filing in this sequence was filed on 17 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001834161 Primary reporting owner

Eisner Mark

Relationship: Director
Address: C/O ZURA BIO LIMITED, 1489 W. WARM SPRINGS RD. #110, HENDERSON
Signature: /s/ Kim Davis, Attorney-in-Fact
Signature date: 24 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZURA transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +37,812
Change %
Price: $0.000000
Shares after: 37,812
Date: 21 Feb 2026
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 37,812
Exercise price: $6.53
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests in twelve substantially equal monthly installments over a one-year period measured from February 21, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.